VTRS
ViatrisANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The Q1 print and guidance reaffirmation suggest Viatris can still deliver operating leverage, while Greater China and branded-drug strength provide near-term support. The meloxicam NDA adds a discrete pipeline readout that could widen the valuation range if it clears FDA review.
Posture
Constructive
Lead driver
Momentum
What changed
3 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Fast-acting meloxicam is still a binary FDA review until the Dec. 27, 2026 PDUFA date.
Momentum
83
Value
65
Sentiment
48
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $15.80 · Bull $19.00 · Bear $12.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-28 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $15.50
Why
Momentum83 · Δ7d -4.5
Value65 · Δ7d +0.4
Sentiment48 · Δ7d +5.7
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
83
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.5
Δ21d
-1.7
Value
65
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.7
Sentiment
48
33% active weight
Current posture
7d trendImproving
Δ7d
+5.7
Δ21d
+11.9
Why this grade
Composite grade A. Momentum 82.6 / Value 65.4 / Sentiment 48.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$18.41B
Beta
0.78
Shares Out
1.15B
P/E (TTM) · Derived
-5.3
P/S (TTM)
1.01
P/FCF (TTM)
13.63
Rev YoY
+0.2%
EPS YoY
-239.4%
Gross Margin
+39.4%
Op Margin
-21.3%
Net Debt
$13.22B
Current Ratio
1.35
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology